San Francisco, United States
Chai Discovery, founded in 2024 and headquartered in the United States, operates at the cutting edge of Biotechnology. Their slogan, "Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules," encapsulates their mission to revolutionize molecular interactions through advanced AI.
The company recently secured a substantial $130.00M Series B investment on 01 December 2025. This funding round attracted prominent investors such as Oak HC/FT, Emerson Collective, General Catalyst, Menlo Ventures, SV Angel, Thrive Capital, Open AI, Yosemite, Glade Brook Capital Partners, Lachy Groom, Neo vc, and Dimension Capital Management.
Chai Discovery's innovative approach and solid financial backing highlight its potential to become a leader in leveraging artificial intelligence for biochemistry advancements.
